Cladribine in tablets in real clinical practice: Results of treatment of 267 patients with multiple sclerosis in Moscow

Introduction. Over the past 30 years, there has been a dramatic change in approaches to the treatment of multiple sclerosis (MS), due to the development of a large number of drugs with different mechanisms of action for the disease-modifying treatment (DMT) of MS.

Aim. To form, based on the analysis of the obtained data, an optimal algorithm for the management of patients with MS receiving cladribine tablets in the conditions of real clinical practice.

Materials and methods. A retrospective analysis of the data obtained on the background of therapy with cladribine in MS patients at the end of 2024 was conducted on the basis of the Moscow inter-district departments of MS. The data from outpatient records of MS patients treated with cladribine from 2021 to 2023 were used as research material. Data collection was carried out on the initial clinical and demographic characteristics of patients, as well as indicators of the effectiveness of therapy (average annual frequency of exacerbations, activity according to MRI data and progression according to the EDSS scale) and the presence of adverse reactions against the background of therapy with cladribine.

Results. This publication presents the experience of using the drug cladribine in real clinical practice in 267 MS patients in Moscow in the period from 2021 to 2023. Patients who underwent two full annual courses of therapy showed a significant reduction in the mean annual frequency of exacerbations and brain MRI activity after the first year of therapy. There was also no significant increase in neurological deficits according to the EDSS scale. During the safety analysis, good tolerability of the drug was noted. The spectrum of adverse events and their frequency were comparable to the data of the instructions for medical use. Conclusion. Effective treatment of MS patients requires optimizing therapy, balancing benefits and risks, and long-term treatment planning from the moment of diagnosis. All these principles can be met with an understanding of the mechanism of action of the drugs and clear adherence to recommendations for monitoring the duration of washout periods when switching from one MS-modifying drug to another.

1. Freedman MS, Devonshire V, Duquette P, Giacomini PS, Giuliani F, Levin MC et al. Treatment Optimization in Multiple Sclerosis: Canadian MS Working Group Recommendations. Can J Neurol Sci. 2020;47(4):437–455. https://doi.org/10.1017/cjn.2020.66.

2. Pardo G, Jones DE. The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations. J Neurol. 2017;264(12):2351–2374. https://doi.org/10.1007/s00415-017-8594-9.

3. Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A et al. Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopa-thy. N Engl J Med. 2012; 366(20):1870–1880. https://doi.org/10.1056/NEJMoa1107829.

4. Sipe JC. Cladribine for multiple sclerosis: review and current status. Exp Rev Neurother. 2005;5(6):721–727. https://doi.org/10.1586/14737175.5.6.721.

5. Jacobs BM, Ammoscato F, Giovannoni G, Baker D, Schmierer K. Cladribine: mechanisms and mysteries in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2018;89(12):1266–1271. https://doi.org/10.1136/jnnp-2017-317411.

6. Warnke C, Wiendl H, Hartung HP, Stüve O, Kieseier BC. Identification of targets and new developments in the treatment of multiple sclerosis – focus on cladribine. Drug Des Devel Ther. 2010;4:117–126. https://doi.org/10.2147/DDDT.S6627.

7. Carson DA, Wasson DB, Taetle R, Yu A. Specific toxicity of 2-chlorode-oxyadenosine toward resting and proliferating human lymphocytes. Blood. 1983;62(4):737–743. https://doi.org/10.1182/blood.V62.4.737.737.

8. Sipe JC. Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis. Expert Rev Neurother. 2010;10(3):365–375. https://doi.org/10.1586/ern.10.12.

9. Manouchehri N, Salinas VH, Rabi Yeganeh N, Pitt D, Hussain RZ, Stuve O. Efficacy of Disease Modifying Therapies in Progressive MS and How Immune Senescence May Explain Their Failure. Front Neurol. 2022;13:854390. https://doi.org/10.3389/fneur.2022.854390.

10. Baker D, Marta M, Pryce G, Giovannoni G, Schmierer K. Memory B cells are major targets for effective immunotherapy in relapsing multiple sclerosis. EBioMedicine. 2017;16:41–50. https://doi.org/10.1016/j.ebiom.2017.01.042.

11. Liliemarkj. The clinical pharmacokinetics of cladribine. Clin Pharmacokinet. 1997;32(2):120–131. https://doi.org/10.2165/00003088-199732020-00003.

12. Hermann R, Karlsson MO, Novakovic AM, Terranova N, Fluck M, Munafo A. The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis. Clin Pharmacokinet. 2019;58(3):283–297. https://doi.org/10.1007/s40262-018-0695-9.

13. Fissolo N, Calvo-Barreiro L, Eixarch H, Boschert U, Villar LM, Costa-Frossard L et al. Molecular signature associated with cladribine treatment in patients with multiple sclerosis. Front Immunol. 2023;14:1233546. https://doi.org/10.3389/fimmu.2023.1233546.

14. Ceronie B, Jacobs BM, Baker D, Dubuisson N, Mao Z, Ammoscato F et al. Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells. J Neurol. 2018;265(5):1199–1209. https://doi.org/10.1007/s00415-018-8830-y.

15. Wiendl H, Schmierer K, Hodgkinson S, Derfuss T, Chan A, Sellebjerg F et al. Specific Patterns of Immune Cell Dynamics May Explain the Early Onset and Prolonged Efficacy of Cladribine Tablets: A MAGNIFY-MS Substudy. Neurol Neuroimmunol Neuroinflamm. 2023;10(1):e200048. https://doi.org/10.1212/NXI.0000000000200048.

16. Kawasaki H, Carrera CJ, Piro LD, Saven A, Carson DA. Relationship of deoxycytidine kinase and cytoplasmic 5’-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blood. 1993;81(3):597–601. https://doi.org/10.1182/blood.V81.3.597.597.

17. Griffig J, Koob R, Blakley RL. Mechanisms of inhibition of DNA synthesis by 2-chlorodeoxyadenosine in human lymphoblastic cells. Cancer Res 1989; 49(24 Pt 1):6923–6928. Available at: https://pubmed.ncbi.nlm.nih.gov/2573423/.

18. Laugel B, Borlat F, Galibert L, Vicari A, Weissert R, Chvatchko Y, Bruniquel D. Cladribine inhibits cytokine secretion by T cells independently of deoxycytidine kinase activity. J Neuroimmunol. 2011;240-241:52–57. https://doi.org/10.1016/j.jneuroim.2011.09.010.

19. Mitosek-Szewczyk K, Tabarkiewicz J, Wilczynska B, Lobejko K, Berbecki J, Nastaj M et al. Impact of cladribine therapy on changes in circulating dendritic cell subsets, T cells and B cells in patients with multiple sclerosis. J Neurol Sci. 2013;332(1-2):35–40. https://doi.org/10.1016/j.jns.2013.06.003.

20. Leist TP, Weissert R. Cladribine: mode of action and implications for treatment of multiple sclerosis. Clin Neuropharmacol. 2011;34(1):28–35. https://doi.org/10.1097/wnf.0b013e318204cd90.

21. Cook S, Vermersch P, Comi G, Giovannoni G, Rammohan K, Rieckmann P et al. Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study. Mult Scler. 2011;17(5):578–593. https://doi.org/10.1177/1352458510391344.

22. Popova EV, Abroskina MV, Bakhtiyarova KZ, Vlasov YaV, Davydovskaia MV, Evdoshenko EP et al. Early use of cladribine tablets for relapsing-remitting multiple sclerosis: Expert opinion. Meditsinskiy Sovet. 2024;18(12):101–107. (In Russ.) https://doi.org/10.21518/ms2024-321.